首页|A switch in mechanism of action prevents doxorubicin-mediated cardiac damage

A switch in mechanism of action prevents doxorubicin-mediated cardiac damage

扫码查看
原文链接
  • NSTL
  • Elsevier
Cancer patients treated with doxorubicin are at risk of congestive heart failure due to doxorubicin-mediated cardiotoxicity via topoisomerase II? poisoning. Acute cardiac muscle damage occurs in response to the very first dose of doxorubicin, however, cardioprotection has been reported after co-treatment of doxorubicin with acyloxyalkyl ester prodrugs. The aim of this study was to examine the role played by various forms of acute cardiac damage mediated by doxorubicin and determine a mechanism for the cardioprotective effect of formaldehyde-releasing prodrug AN-9 (pivaloyloxymethyl butyrate).

Triple negative breast cancerAnthracycline chemotherapyDoxorubicin-induced cardiotoxicityFormaldehyde-releasing prodrugDoxorubicin-DNA adduct

Cheong, Alison、McGrath, Sean、Robinson, Tina、Maliki, Ruqaya、Spurling, Alex、Lock, Peter、Nudelman, Abraham、Parker, Belinda S.、Pepe, Salvatore、Cutts, Suzanne M.、Rephaeli, Ada

展开 >

La Trobe Univ, La Trobe Inst Mol Sci, Dept Biochem & Genet, Melbourne, Vic 3086, Australia

Bar Ilan Univ, Dept Chem, Div Med Chem, IL-52900 Ramat Gan, Israel

Royal Childrens Hosp, Murdoch Childrens Res Inst, Dept Cardiol, Parkville, Vic, Australia

Felsenstein Med Res Ctr, Lab Pharmacol & Expt Oncol, Petah Tiqwa, Israel

展开 >

2021

10.1016/j.bcp.2021.114410

Biochemical Pharmacology

Biochemical Pharmacology

ISTP
ISSN：0006-2952
年,卷(期)：2021.185
  • 69